| __timestamp | Amphastar Pharmaceuticals, Inc. | Merus N.V. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 3852327 |
| Thursday, January 1, 2015 | 46974000 | 839656 |
| Friday, January 1, 2016 | 47298000 | 4478145 |
| Sunday, January 1, 2017 | 50918000 | 16432324 |
| Monday, January 1, 2018 | 58044000 | 11890871 |
| Tuesday, January 1, 2019 | 63109000 | 34110000 |
| Wednesday, January 1, 2020 | 65157000 | 35781000 |
| Friday, January 1, 2021 | 68920000 | 40896000 |
| Saturday, January 1, 2022 | 66592000 | 52200000 |
| Sunday, January 1, 2023 | 80393000 | 59836000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amphastar Pharmaceuticals, Inc. and Merus N.V. have taken different paths in optimizing these costs over the past decade. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, peaking at 80 million in 2023. In contrast, Merus N.V. saw a staggering increase of over 1,450% in the same period, reaching nearly 60 million. This dramatic rise reflects Merus's aggressive expansion and investment strategies. While Amphastar maintains a steady growth trajectory, Merus's volatile SG&A expenses suggest a focus on rapid scaling. Investors and analysts should consider these trends when evaluating the financial health and strategic direction of these companies. Understanding how each company manages its SG&A costs can provide insights into their operational efficiency and long-term sustainability.
Johnson & Johnson or Merus N.V.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Merus N.V.
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Dr. Reddy's Laboratories Limited and Merus N.V.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. vs Merus N.V.: SG&A Expense Trends
PTC Therapeutics, Inc. vs Merus N.V.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Merus N.V. vs Soleno Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Amphastar Pharmaceuticals, Inc. or Taro Pharmaceutical Industries Ltd.